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Abstract
Closely related African trypanosomes cause lethal diseases but display distinct host ranges. Specifically, Trypanosoma brucei
brucei causes nagana in livestock but fails to infect humans, while Trypanosoma brucei gambiense and Trypanosoma brucei
rhodesiense cause sleeping sickness in humans. T. b. brucei fails to infect humans because it is sensitive to innate immune
complexes found in normal human serum known as trypanolytic factor (TLF) 1 and 2; the lytic component is apolipoprotein-
L1 in both TLFs. TLF resistance mechanisms of T. b. gambiense and T. b. rhodesiense are now known to arise through either
gain or loss-of-function, but our understanding of factors that render T. b. brucei susceptible to lysis by human serum
remains incomplete. We conducted a genome-scale RNA interference (RNAi) library screen for reduced sensitivity to human
serum. Among only four high-confidence ‘hits’ were all three genes previously shown to sensitize T. b. brucei to human
serum, the haptoglobin-haemoglobin receptor (HpHbR), inhibitor of cysteine peptidase (ICP) and the lysosomal protein,
p67, thereby demonstrating the pivotal roles these factors play. The fourth gene identified encodes a predicted protein with
eleven trans-membrane domains. Using chemical and genetic approaches, we show that ICP sensitizes T. b. brucei to human
serum by modulating the essential cathepsin, CATL, a lysosomal cysteine peptidase. A second cathepsin, CATB, likely to be
dispensable for growth in in vitro culture, has little or no impact on human-serum sensitivity. Our findings reveal major and
novel determinants of human-serum sensitivity in T. b. brucei. They also shed light on the lysosomal protein-protein
interactions that render T. b. brucei exquisitely sensitive to lytic factors in human serum, and indicate that CATL, an
important potential drug target, has the capacity to resist these factors.
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Introduction
The African trypanosomes are flagellated protozoan parasites
comprising several species of the genus Trypanosoma, which cause
devastating diseases in humans and livestock. One key feature that
distinguishes members of this group is their sensitivity to innate
trypanolytic factors (TLFs) found in human serum. T. b. brucei and
related species cause nagana in livestock but these parasites are
rapidly lysed by human TLFs [1,2]. T. b. gambiense and T. b.
rhodesiense, on the other hand, although sharing .99% genome
sequence identity with T. b. brucei [3], have evolved distinct
mechanisms to escape lysis by human serum; these are the
causative agents of human African trypanosomiasis (HAT), also
known as sleeping sickness, in Western and Eastern Africa,
respectively. T. b. gambiense is responsible for 97% of reported cases
of HAT [4].
There are two classes of TLF found in normal human serum,
TLF-1, which is a component of high density lipoprotein [5,6],
and TLF-2, which is an apolipoprotein-A1/IgM complex
[7,8]; the active lytic component in both TLFs is apolipopro-
tein-L1 (APOL1) [9]. Both TLFs also contain haptoglobin-
related protein, which, in the case of TLF-1, mediates binding
to the T. b. brucei haptoglobin-haemoglobin receptor (HpHbR)
and uptake into the cell [10,11]. Following uptake, APOL1 is
inserted into endosomal and lysosomal membranes, where Bcl-
2-like pore-formation is thought to be responsible for osmotic
swelling and lysis [12,13].
Human TLF resistance mechanisms of T. b. gambiense and T. b
rhodesiense have now been described, and these involve reduced
TLF binding/uptake, APOL1 sequestration, or reduced APOL1
toxicity, possibly due to membrane stiffening. Reduced TLF
binding/uptake operates in T. b. gambiense due to reduced
expression of HpHbR and/or mutations in HpHbR [14–16].
Endosomal sequestration of APOL1 operates in T. b. rhodesiense
due to the expression of a serum resistance-associated protein
(SRA) related to a glycosyl-phoshatidylinositol membrane-an-
chored variant surface glycoprotein (VSG) [2,17]. Expression of a
VSG-related protein also confers TLF-resistance to T. b. gambiense
[18,19], but in this case the VSG-like T. b. gambiense-specific
glycoprotein or TgsGP may protect cells from APOL1 by
stiffening endosomal membranes rather than through direct
interaction with, or sequestration of, APOL1 [19].
The lysosomal membrane protein, p67 [20] and inhibitor of
cysteine peptidase (ICP) [19] have also been shown to contribute
to human TLF susceptibility using loss-of-function approaches in
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T. b. brucei. While HpHbR plays a role in TLF binding/uptake, the
mechanism by which p67 contributes to human serum sensitivity
in T. b. brucei remains unknown. Depletion of p67 causes lysosomal
dysfunction, but does not increase lysosomal pH [20]; acidification
has been proposed to be important for the insertion of APOL1
into membranes and the resulting lytic activity [12,13,21]. The
role of the individual cysteine peptidases, the targets of ICP, has
not previously been investigated, although T. b. brucei and T. b.
gambiense cells exposed to a cysteine peptidase inhibitor display
increased accumulation of TLF-1 [2] and APOL1 [19], strongly
suggesting that a cysteine peptidase contributes to the destruction
of APOL1. Cysteine peptidase inhibition by ICP likely similarly
increases APOLI accumulation, explaining increased human
serum resistance following ICP knockdown [19]. Thus, gain-of-
function, through the expression of modified VSGs, or loss of
TLF-receptor function, have contributed to the emergence of
human-infective African trypanosomes. However, other undiscov-
ered resistance mechanisms are thought to operate in these
parasites [22]; expression of TgsGP does not confer human serum
resistance to T. b. brucei [23], and the main route of entry for TLF-
2 in T. b. brucei is thought to be independent of HpHbR [10,19].
We sought to confirm those factors known to render T. b. brucei
susceptible to lysis by human serum and to screen for additional
factors. A genome-scale RNA interference library screen for
increased resistance to human serum identified all three known
genes and only one additional gene, encoding a novel putative
trans-membrane channel, with high-confidence. This library was
previously shown to yield read-outs representing approximately 5-
fold genome coverage, or more than 99% of the .7,000 non-
redundant protein coding sequences in the T. b. brucei genome
[24], and an approach related to the one described here was used
to identify efficacy determinants for all five current anti-HAT
drugs [25]. We next explored the unexplained role of the cysteine
peptidase inhibitor in this process, and show that ICP impacts
human serum resistance by specifically modulating the activity of
the lysosomal cysteine peptidase, cathepsin-L (CATL).
Results
A genome-scale screen for genes controlling human
serum sensitivity in T. b. brucei
Natural hosts for bloodstream form (BSF) T. b. brucei include
bovids, and these parasites are typically propagated in a
culture medium containing 10% bovine serum. In this culture
environment, the half maximal effective growth-inhibitory con-
centration (EC50) of normal human serum (NHS) against cultured
BSF T. b. brucei was less than 0.00025% (Figure 1A), revealing the
exquisite sensitivity of these parasites to lytic factors in NHS. To
identify T. b. brucei factors that contribute to the trypanolytic
activity of NHS, we selected a multi-genome coverage BSF T. b.
brucei RNAi library in 0.0005% NHS (see Figure 1B). Using this
loss-of-function approach, knockdown of factors that normally
contribute to human serum sensitivity will generate cells with
increased resistance to this toxin. Under RNAi-inducing condi-
tions, population growth was severely curtailed for six days in the
presence of NHS; the human serum was added to the growth
medium 24 h after inducing RNAi with tetracycline (Figure 1C). A
population that displayed tetracycline-dependent tolerance of this
concentration of NHS emerged thereafter (Figure 1D), and was
harvested for DNA extraction and RNA interference target
sequencing (RIT-seq) two days later.
Using a modified RIT-seq [24] methodology (see Materials and
Methods), we generated and mapped individual sequence reads
representing the human serum-enriched RNAi target fragments,
about 0.5 million reads in total. Approximately 24% of these reads
incorporated a 14-bp RNAi construct signature found at the
junction with each gene-specific RNAi target fragment, and this
allowed us to focus on only ‘high-confidence hits’: genes identified
in the screen by more than 99 reads per kilobase per CDS
(Figure 2A), with more than 99 reads containing the RNAi
construct signature, and at least two independent RNAi target
fragments (Table 1). We previously applied similarly stringent
criteria to define the key efficacy determinants of the anti-HAT
drugs [25].
As detailed above, three T. b. brucei genes have been shown to
play a role in trypanolysis by NHS. Remarkably, we identified
only four high-confidence hits in our screen. The presence of the
three known genes within this set (Figure 2A), haptoglobin-
haemoglobin receptor (HpHbR) [11], inhibitor of cysteine
peptidase (ICP) [19], and the lysosomal membrane protein, p67
[20], provides excellent validation for the RNAi-screening
approach. The schematic in Figure 2B shows the four high-
confidence loci identified in the screen with mapped sequence
reads. The novel high-confidence hit (Tb927.8.5240) encodes a
‘conserved hypothetical’ protein (Figure 2A and Table 1).
Although it is likely membrane-associated, as it contains 11
putative trans-membrane domains, we have been unable to
establish its sub-cellular localisation by C-terminal epitope tagging
(data not shown). Specific stem-loop RNAi depletion of
Tb927.8.5240 in three independent cell lines, confirmed by
quantitative reverse transcriptase PCR (Figure 3A; Text S1), had
no significant effect on bloodstream-form population growth over
seven days (Figure 3B), but resulted in a 2.3-fold average increase
in NHS EC50, demonstrating its contribution to NHS-sensitivity
(Figure 3C, D).
The additional genes highlighted in blue in Figure 2A are listed
in Table 1. These failed to fulfil the stringent criteria for further
analysis detailed above. The only exception being Tb927.8.6870
whose knockdown has previously been shown to lead to a
significant gain of fitness [24]; we subsequently confirmed that loss
of this protein did not influence sensitivity to NHS (data not
shown).
Cathepsins fail to resist human serum trypanolytic
activity in the presence of ICP
ICPs are conserved in protozoal and bacterial pathogens [26].
The T. b. brucei and T. b. gambiense ICP genes are almost identical
and are predicted to encode proteins of 13.5 kDa. They are
Author Summary
The interplay among host innate immunity and resistance
mechanisms in African trypanosomes has a major impact
on the host range of these tsetse-fly transmitted parasites,
defining their ability to cause disease in humans. A
genome-scale RNAi screen identified a highly restricted
set of four genes that sensitise trypanosomes to human
serum: those encoding the haptoglobin-haemoglobin
receptor, a predicted trans-membrane channel, a lysosom-
al membrane-protein and the cysteine peptidase inhibitor.
An analysis of the cysteine peptidases revealed cathepsin-L
as the protease regulated by the inhibitor – and with the
capacity to render the parasite resistant to lysis by human
serum. These findings emphasise the importance of
parasite factors for the delivery and stability of host toxins.
They also shed light on the control of proteolysis by
parasites and potential unanticipated consequences of
therapies that target the parasite proteases.
Cathepsin-L and Resistance to Trypanolysis
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thought to block cysteine peptidase activity by occupying the
substrate-binding cleft [27], and to play a role in regulating
parasite infectivity and VSG coat exchange during differentiation
[28]. African trypanosomes express two cathepsins, CATB and
CATL [29], which are highly conserved between T. b. brucei and
T. b. gambiense, and at least one (CATL) localises to the lysosome
[30]. We used chemical and genetic approaches to explore the
potential roles of T. b. brucei CATB and CATL in resisting lysis by
human serum.
Initially, we tested the dual CATB/L inhibitor, FMK024, in
combination with NHS against T. b. brucei. Isobologram and EC50
analyses revealed that this inhibitor fails to synergise with NHS in
cell-killing assays (Figure 4A, B). Indeed, the addition of increasing
amounts of FMK024 causes little change in parasite sensitivity to
NHS (Figure 4B), suggesting that the inhibitory function of
endogenous ICP may be modulated as a consequence of changes
in protease activity elicited by exogenous inhibitor. FMK024
applied at 10 or 20 mM (62.5 and 125-fold higher than the highest
concentration used here) has been shown to cause lysosomal
accumulation of TLF in T. b. gambiense [19] and of APOL1 in
SRA-expressing T. b. brucei [2], respectively. It should be noted,
however, that such high concentrations of FMK024 would likely
lead to total inhibition of lysosomal cathepsin activity, and it is
unlikely that ICP modulation would have any impact. Indeed,
FMK024 treatment is lethal at these concentrations in our EC50
assays, independent of NHS exposure (see below).
We next used RNAi to knockdown CATB or CATL
individually in T. b. brucei. Specific protein depletion was
confirmed by western blot, and subsequent analyses revealed that
only CATL activity appears to be particularly important for robust
growth (Figure 5A, B). Previous findings suggested that CATB but
not CATL was essential for growth [31,32]; however, our results
are consistent with the recent chemical and genetic validation of
CATL as a more appropriate drug target [25,29]. Although we
used a sub-lethal knockdown in the case of CATL, we were able to
obtain substantial protein depletion compatible with continued
growth [25] (Figure 5B). Consistent with the results obtained
above using chemical inhibition of cathepsin activity, both
knockdowns failed to synergise with NHS in killing T. b. brucei
(Figure 5C, D). These data suggest that if a protease can resist lysis
by human serum, its activity is suppressed.
CATL resists human serum trypanolytic activity in the
absence of ICP
The results above show either that repression of cathepsin
activity by ICP renders T. b. brucei sensitive to human serum and
that cathepsin knockdown is compensated for by down-regulation
of ICP activity, or that CATB and CATL play no role in resistance
Figure 1. A genome-scale T. b. brucei RNAi library screening strategy for human serum resistance. (A) T. b. brucei (MITat 1.2; 2T1) have an
EC50 of less than 0.00025% normal human serum (NHS) when incubated for 72 hours at 37uC. (B) Schematic showing selection of NHS-resistant
parasites from the RNAi library. (C) A population resistant to NHS was selected. RNAi was induced in 1 mg/ml tetracycline (Tet) for 24 hours prior to
selection initiated at day 0; red arrows indicate culture dilution and addition of fresh NHS and tetracycline at 0.0005% and 1 mg/ml, respectively. (D)
The NHS resistance phenotype of the selected library was tetracycline-inducible; error bars represent standard deviation.
doi:10.1371/journal.ppat.1004130.g001
Cathepsin-L and Resistance to Trypanolysis
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Figure 2. An RNAi screen reveals major determinants of human serum sensitivity in T. b. brucei. (A) Genome-wide NHS RIT-seq profile
representing 7,433 non-redundant protein-coding sequences, showing those represented by more than 100 reads per kbp; three known human
serum sensitivity determinants, HpHbR (Tb927.6.440), p67 (Tb927.5.1810/1830) and ICP (Tb927.8.6450), and the only other high-confidence and novel
‘hit’ (Tb927.8.5240) are highlighted in red. (B) Profiles of mapped RIT-seq reads for the four high-confidence hits identified in (A); boxes represent
protein coding sequences; total reads (red) and tagged reads (blue; containing the 14-bp RNAi construct signature sequence) mapped to each region
are shown in the top right corner of each panel; see Table 1 for further details.
doi:10.1371/journal.ppat.1004130.g002
Cathepsin-L and Resistance to Trypanolysis
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to lysis by human serum. To distinguish between these possibilities,
we generated icp null T. b. brucei [33] (Figure 6A, B). As previously
shown for a distinct cathepsin inhibitor [28], the icp null strains
displayed a minor but significant increase in FMK024 EC50
(Figure 6C, D), confirming up-regulation of a cathepsin activity
required for robust growth, most-likely that due to the essential
CATL (see above). The icp null strains were, on average, 7.2-fold
less sensitive to NHS (Figure 6E, F), validating this RNAi
screening output and also consistent with a recent report [19].
In striking contrast to the situation in wild-type T. b. brucei,
isobologram and EC50 analyses revealed strong synergy between
FMK024 and NHS in killing icp null T. b. brucei (Figure 7A).
Indeed, in the presence of 5 to 160 nM FMK024, the NHS
sensitivity was almost completely reversed to that of wild-type cells
(Figure 7B). These results suggest that one or both of the
cathepsins can indeed confer resistance to lysis by human serum,
but only effectively in the absence of ICP. We next set out to
determine which of the cathepsins is responsible for this
phenotype. In order to assess the contribution of the individual
cathepsins to resisting NHS, we generated strains for the inducible
RNAi-mediated knockdown of either CATB or CATL in an icp
null background. Once again, we had to use a sub-lethal
knockdown in the case of CATL (see Figure 5B).
CATB knockdown in these strains had no impact on NHS-
sensitivity (Figure 7C, D). Hence, although CATB may have a
role in the degradation of other host-derived proteins,
including transferrin [32], our data suggests that it does not
target human serum lytic factors. In contrast, CATL knock-
down was associated with a highly significant increase in
sensitivity to NHS (Figure 7E, F). Failure to completely reverse
the NHS-resistance phenotype following CATL RNAi, may be
explained by a second contributing factor or, more likely in our
view, is because these experiments had to be carried out
under partial knockdown conditions. We conclude that ICP
increases sensitivity to NHS primarily by inhibiting CATL
activity.
Discussion
T. b. gambiense and T. b. rhodesiense can resist the APOL1-based
trypanolytic factors found in normal human serum, while T. b.
brucei fails to do so. We report here an RNAi library screen in
bloodstream-form T. b. brucei for resistance to human serum and
identify all three known genes, as well as a novel gene, that
increase T. b. brucei susceptibility to this innate immune defence
mechanism. We go on to show that one of these genes, encoding
inhibitor of cysteine peptidase, acts by modulating the essential
activity of CATL, a lysosomal cysteine peptidase. These findings
illuminate the interactions between ICP, CATL and human
serum, and have important implications for human infectivity, as
well as for therapies based on cathepsin inhibitors [34] or serum
lytic factors [35]. Finally, we have revealed a novel role for a
putative trans-membrane domain protein, Tb927.8.5240, in
determining sensitivity to NHS.
A loss-of-function phenotype, associated with HpHbR [14–16],
contributes to human serum resistance in T. b. gambiense, the most
prevalent cause of sleeping sickness. As expected, our RNAi library
screen for human serum resistance identified the gene encoding
Table 1. Summary of RIT-seq outputs following RNAi library selection in NHS.
Reads RNAi Fitness
Gene ID Annotationa Total ‘Tagged’b Total/kbpc targets/CDSd ratioe
High-confidence hits
Tb927.6.440 HpHbR 360,508 71,729 297,449 3 0.14
Tb927.8.6450 ICP 1,217 343 3,325 2 2
Tb927.5.1810 p67 1,648 531 832 4 0
Tb927.5.1830 p67 1,448 441 729 3 0.31
Tb927.8.5240 Conserved hypothetical 2,762 386 833 2 1.38
Other hitsf
Tb927.5.1540 Conserved hypothetical 100,080 35,814 45,326 1 1.24
Tb927.6.2930 Conserved hypothetical 1,930 241 1,214 1 0.41
Tb927.8.6870 Conserved hypothetical 1,805 409 719 4 32.6
Tb927.4.2090 Hypothetical 252 94 488 1 0.68
Tb927.11.12880 Conserved hypothetical 161 88 378 1 2.11
Tb927.9.11000 VSG pseudogene 90 34 214 1 0.53
Tb927.1.3730 Hypothetical 30 15 172 1 0.08
Tb927.4.4350 Hypothetical 82 41 134 1 0.81
Tb927.7.4500 Hypothetical 166 55 105 3 0.83
Tb927.8.2380 ABC transporter 350 64 101 3 0.89
aAnnotations derived from GeneDB, http://www.genedb.org/Homepage/Tbruceibrucei927.
b‘Tagged’ reads incorporate a 14-bp RNAi construct signature.
cPlotted in Figure 2A.
dHigh-confidence ‘hits’ characterised by .99 reads containing the 14-base RNAi construct signature, and .1 distinct RNAi target fragment.
eBloodstream-form (BSF) T. b. brucei RNAi library fitness ratio derived from reference [24]; six-day induced read count divided by uninduced read count.
fOther ‘hits’ are characterised by massive gain-of-fitness during RNAi induction (Tb927.8.6870) [24], a single RNAi target sequence (Tb927.5.1540, Tb927.6.2930), or,100
reads containing the 14-bp RNAi construct signature (relevant criteria highlighted in bold).
doi:10.1371/journal.ppat.1004130.t001
Cathepsin-L and Resistance to Trypanolysis
PLOS Pathogens | www.plospathogens.org 5 May 2014 | Volume 10 | Issue 5 | e1004130
this protein and also the gene encoding the lysosomal membrane
protein, p67, also previously linked to this phenotype through
experimental loss-of-function analysis [20]. This confirmed the
power and utility of the RNAi-screening approach. Our screen
also identified the gene encoding ICP, which was recently linked to
human serum sensitivity by others [19], and a fourth, novel gene
(Tb927.8.5240), encoding a predicted multi-pass trans-membrane
protein, with an almost identical homolog in T. b. gambiense. These
outputs indicate a remarkably low rate of false positives, and
suggest a similarly low rate of false negatives when using a multi-
genome coverage RNAi library to identify high-confidence hits in
T. b. brucei (see Materials and Methods).
To improve our understanding of sensitivity to human serum in
African trypanosomes, we focussed on the role of the cysteine
peptidase inhibitor, ICP. Our chemical and genetic evidence are
entirely consistent, and reveal CATL as the cathepsin primarily
responsible for the decreased sensitivity to human serum seen
following ICP deletion. Specifically, chemical inhibition or
knockdown of the individual cathepsins in an icp null background
revealed that only CATL can resist human serum; CATB
depletion had no detectable effect on this phenotype. CATL has
been shown to accumulate in the lysosome [30], and is responsible
for proteolysis of the transferrin receptor [36] and of anti-parasite
IgG [28]. The lysosome is also the major site of action of APOL1
[13], the lytic component of both TLF1 and TLF2. Thus, CATL
may target TLF, and possibly APOL1, for destruction in the
lysosome (Figure 8). ICP, therefore, naturally maintains sensitivity
to human serum, possibly by restricting the proteolytic degrada-
tion of TLF (or APOL1) in the lysosome. This is consistent with
previous pulse chase experiments that found little proteolytic
degradation of the lytic factor and its components in T. b. brucei
[37], thereby allowing APOL1 to form membrane-spanning pores,
leading to lysosomal swelling and cell lysis. Unmasking of the
CATL activity only in the absence of ICP confirms natural control
of this cathepsin, as suspected, by ICP.
Using a similar RNAi-screening approach, uptake of the anti-
trypanosomal drug, suramin, was shown to be via receptor-
mediated endocytosis in T. b. brucei [25]. The identification of only
p67 by both screens suggests distinct uptake and trafficking factors
and mechanisms involved in suramin uptake following association
with the type-I trans-membrane glycoprotein, ISG75 [25], and
TLF-uptake following association with the GPI-anchored HpHbR
Figure 3. Specific RNAi-mediated depletion of Tb927.8.5240 renders cells less sensitive to NHS. (A) Tb927.8.5240 depletion, as
demonstrated by reverse transcriptase qPCR (see also Tables S1 and S2 in Text S1), has no significant effect on parasite population growth (B); bars
represent standard deviation from three independent strains. (C, D) RNAi against Tb927.8.5240 increases NHS EC50; bars represent standard error (C)
or standard deviation (D); p values derived from extra sum-of-squares F-test (C) or paired t-test (D).
doi:10.1371/journal.ppat.1004130.g003
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[11]. Interestingly, CATL has now been linked to both suramin
efficacy [25] and human serum toxicity (this study) but, while
CATL can protect T. b. brucei from killing by human serum, it
sensitises T. b. brucei to killing by suramin. This suggests that
suramin, a napthylamine, is liberated in active form by lysosomal
proteolysis, while we suggest that TLF (APOL1) is degraded by
lysosomal proteolysis.
Trypanosomal cathepsins are targets of ongoing drug develop-
ment [29,38,39]. Although it was previously suggested that CATB
was an appropriate drug target [31], more recent genetic and
chemical evidence indicates that CATL is the essential cysteine
peptidase of T. b. brucei and the most appropriate target [25,29].
Our current findings also support this view. In this context, it is
worth considering the potential impact of therapy targeting the
essential cysteine peptidase activity. Our results indicate little
impact of exposure to such inhibitors on human serum sensitivity
in T. b. brucei. However, cysteine peptidases may be more active in
T. b. gambiense [19] and/or T. b rhodesiense, possibly due to selective
pressure through TLF exposure, and CATL inhibition could act
synergistically with TLF in this case, increasing sensitivity to lytic
activity and presenting a novel rational approach to therapy. On
the other hand, T. b. gambiense and T. b. rhodesiense rely upon
lysosomal/endosomal VSG variants to resist the toxic effects of
APOL1. Reduced proteolysis of these factors [19] could increase
parasite resistance to human serum, meaning that targeting CATL
could represent a risky therapeutic strategy. Indeed, FMK024
exposure leads to an accumulation of SRA in the lysosome of T. b.
brucei engineered to express this VSG-variant [2]. It will clearly be
important to develop an improved understanding of the interplay
among these factors in human-infective trypanosomes.
We link four factors to human serum sensitivity using a genome-
scale loss-of-function screen in T. b. brucei. These include all three
expected factors, based on previous reports, and a novel putative
trans-membrane channel. It is interesting to note that, in the case of
ICP, we uncovered a gain-of-function phenotype using a loss-of-
function screen; this is possible when one protein antagonises the
action of another. Our findings indicate that CATL can resist lysis
by human serum, and this has important implications, since
CATL is a promising potential drug target. In addition, the novel
link to a putative trans-membrane channel presents an excellent
candidate that may facilitate TLF transit. Notably, the gene
encoding TgsGP is not present in T. b. gambiense group 2 [40],
indicating a distinct human serum resistance mechanism in these
parasites, and the main route of entry for TLF2 in T. b. brucei is
thought to be independent of HpHbR [11,19]. The outputs from
our screen and our studies on ICP and CATL shed light on
mechanisms of toxin delivery and stability in African trypano-
somes and should facilitate studies aimed at understanding the
multiple mechanisms employed by T. b. gambiense and T. b.
rhodesiense to resist lytic factors in humans and other primates.
Materials and Methods
T. b. brucei strains
MITat 1.2 clone 221a 2T1 bloodstream-form T. b. brucei were
maintained and manipulated as previously described [33].
Transformants were selected in blasticidin (10 mg/ml), hygro-
mycin (2.5 mg/ml) or G418 (2 mg/ml), as appropriate. For growth
assays, cells were seeded at ,105/ml, counted using a haemocy-
tometer, and diluted back every 24 hours, as necessary, for up to
seven days in the absence of antibiotics.
NHS sensitivity analysis
To determine NHS EC50, cells were seeded at 2610
3 ml21 in
96-well plates in a 2-fold dilution series of NHS (pooled mixed
gender; Sera Laboratories International), starting from 0.01%;
assays were carried out in the absence of antibiotics. After ,3 days
growth, 20 ml of 125 mg/ml resazurin (Sigma) in PBS was added to
each well and the plates incubated for a further 6 hours at 37uC.
Fluorescence was determined using a fluorescence plate reader
(Molecular Devices) at an excitation wavelength of 530 nm, an
emission wavelength of 585 nm and a filter cut-off of 570 nm [41].
To analyse the combined effect of NHS and FMK024 treatment,
isobologram analysis was carried out using a checkerboard
approach, as previously described [42]. Data were processed in
Excel, and non-linear regression analysis carried out in GraphPad
Prism.
Selective screening of a genome scale T. b. brucei RNAi
library
The bloodstream-form T. b. brucei RNAi library [24] was
thawed into 100 ml HMI-11 media (Life Technologies)
Figure 4. Chemical inhibition of T. b. brucei cathepsins in the
presence of ICP has no effect on human serum trypanolytic
activity. (A) FMK024 fails to synergise with NHS against wild-type T. b.
brucei; isobologram analysis showing 50% fractional inhibitory concen-
trations (FIC); dashed line indicates the expected output for no
interaction. (B) Individual NHS EC50 curves generated in the presence
of 5 to 160 nM FMK024; bars represent standard error.
doi:10.1371/journal.ppat.1004130.g004
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containing 10% foetal bovine serum (FBS; Sigma) at a density
of approximately 16105/ml. RNAi was induced in 1 mg/ml
tetracycline for 24 hours prior to the addition of 0.0005%
NHS; RNAi induction and NHS selection were maintained
throughout. Daily counts were carried out using a haemocy-
tometer, and the total population was maintained at no lower
than 20 million cells for the duration of selection. Once robust
growth had been achieved, the inducibility of the selected
phenotype was tested [25] (Figure 1D) and genomic DNA
prepared for RNAi target identification.
Sequencing and mapping
The RNAi cassettes remaining in the NHS-selected library
were specifically amplified from genomic DNA using the
LIB2f/LIB2r primers [43] producing a ladder of bands
ranging in size from 0.25–1.5-kbp following agarose gel-
electrophoresis (data not shown). High-throughput sequencing
of the amplified DNA was carried out on an Illumina platform
(Beijing Genome Institute). Using paired 150-bp sequencing
reads; presence or absence of a 14-bp RNAi-construct
signature was recorded in the FASTQ header line. Sequence
reads were then trimmed to remove lower-quality sequences
and mapped to the T. b. brucei reference genome (release 4.2)
using bowtie [44]. BAM files were processed using the
SAMtools bioinformatics suite [45]. The maps were explored
visually in Artemis, and plots were derived using the Artemis
graph tool and processed in Adobe Photoshop Elements 8.0.
Stacks of reads that included the 14-bp signature on the
Figure 5. Specific depletion of T. b. brucei cathepsins in the presence of ICP has no effect on human serum trypanolytic activity. (A)
CATB depletion has no effect on cell growth, while (B) induction of CATL RNAi in 1 mg/ml tetracycline (Tet) results in a significant growth defect; bars
represent standard deviation from four and two independent strains, respectively. CATB12MYC and anti-CATL western blots confirm depletion of the
individual cathepsins; coomassie-stained gels show loading. Representative NHS EC50 analysis following (C) CATB and (D) CATL depletion in wild-type
T. b. brucei; RNAi induced in 1 mg/ml and 2 ng/ml tetracycline, respectively; bars represent standard error.
doi:10.1371/journal.ppat.1004130.g005
Cathepsin-L and Resistance to Trypanolysis
PLOS Pathogens | www.plospathogens.org 8 May 2014 | Volume 10 | Issue 5 | e1004130
positive strand were used to define RNAi target fragment
junctions and to assign high-confidence hits as those identified
by .1 RNAi target fragment.
Plasmid and strain construction
ICP deletion was carried out as described [28], except
that targeting fragments were cloned in pBSD, and the
Figure 6. Disruption of ICP in T. b. brucei renders cells less sensitive to NHS. (A) Schematic showing segment deleted from the ICP locus
(highlighted with an open triangle), and positions of restriction sites (arrow heads), and ICP and downstream (DS) flanking probes. (B) Southern blots
confirming ICP deletion from the 2T1 cell line; BSD, blasticidin-S-deaminase; NPT, neomycin phosphotransferase. (C, D) ICP loss has a minor but
significant effect on FMK024 sensitivity (mean fold EC50 change, 1.31; five independent strains). (E) NHS EC50 analysis of a representative icp null
strain; bars represent standard error. (F) Reduced NHS sensitivity requires deletion of both ICP alleles (five independent strains); loss of one ICP allele
has no significant effect on sensitivity to NHS (two independent strains). Bars represent standard error (C, E) and standard deviation (D, F); p values
derived from extra sum-of-squares F-test (C, E) or paired t-test (D, F).
doi:10.1371/journal.ppat.1004130.g006
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blasticidin-S-deaminase cassette was then replaced with a neomy-
cin phosphotransferase cassette to generate pBSDDICP and
pNPTDICP constructs. We C-terminally cMyc-tagged an
endogenous copy of CATB at a native allele [46]. A 990 bp
CATB C-terminal fragment minus the stop codon was cloned into
pNATx12MYC [46]; the construct was linearised with PstI prior to
Figure 7. CATL resists human serum trypanolytic activity in the absence of ICP. (A) FMK024 and NHS act synergistically against icp null T. b.
brucei; isobologram analysis showing 50% fractional inhibitory concentrations (FIC) where the dashed line indicates the expected output for no
interaction. (B) Treatment with 5–160 nM FMK024 reverses the icp null T. b. brucei NHS resistance phenotype. (C) Representative NHS EC50 analysis
following CATB depletion in icp null compared with wild-type and icp null T. b. brucei parental cell lines. (D) NHS EC50 analysis following CATB
depletion in four independent strains. (E) Representative EC50 analysis following CATL depletion in icp null cells compared with wild-type and icp null
T. b. brucei parental cells. (F) NHS EC50 analysis of two independent CATL RNAi icp null strains. Bars represent standard error (C, E) and standard
deviation (D, F); p value derived from paired t-test; CATB and CATL knockdowns were induced in 1 mg or 2 ng/ml tetracycline, respectively.
doi:10.1371/journal.ppat.1004130.g007
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transfection. Stem-loop RNAi constructs targeting CATB
(Tb927.6.560), CATL (Tb927.6.960-1060) or Tb927.8.5240 were
generated in pRPaiSL [46]; 206 bp (CATB), 578 bp (CATL) and
417 bp (Tb927.8.5240) target fragments were designed using the
RNAit primer design algorithm to minimise off-target effects [47].
pRPaiSL constructs were linearised with AscI to enable targeted
integration at the rDNA spacer ‘landing pad’ locus in 2T1
bloodstream form T. b. brucei [33]. Details of all oligonucleotides
are available on request. Linearised constructs were transferred to
icp null or wild-type 2T1 T. b. brucei using a nucleofector apparatus
(Lonza) in conjunction with cytomix or T-cell nucleofection
solutions. Protein expression following RNAi depletion was
analysed by SDS-PAGE and western blotting with anti-CATL
and anti-cMyc, using standard protocols [48].
cDNA synthesis and qPCR analysis following
Tb927.8.5240 RNAi
For each cell line and treatment, 2 mg RNA was DNase-treated
and reverse-transcribed using the Superscript VILO cDNA
synthesis kit (Invitrogen). 100 ng (RNA-equivalent) cDNA was
subjected to qPCR using the Quantitect SYBR Green PCR kit
(Qiagen) and primer pairs specific for telomerase reverse
transcriptase (TERT; Tb927.11.10190) and Tb927.8.5240 (details
of primer sequences are available on request). TERT was used as a
reference for normalisation of gene expression, as previously
described [49]. qPCR reactions were carried out in a Rotor-gene
3000 (Corbett Research), using the following cycling conditions:
95uC (15 minutes), followed by 40 cycles of 94uC (15 seconds),
58uC (30 seconds), and 72uC (30 seconds). Standard curves,
derived from a series of 10-fold dilutions of the target PCR
products, were used to determine reaction efficiency. Fold-change
in gene expression was calculated by the DDCt method [50].
Supporting Information
Text S1 Analysis of Tb927.8.5240 knockdown by re-
verse-transcriptase quantitative PCR. Mean Ct data were
used to calculate the DDCt values and fold-change in gene
expression of Tb927.8.5240 following RNAi induction, relative to
the normalisation gene (TERT).
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